Bruno Pitard is an engineering graduate of Université de Technologie de Compiègne, holds a PhD from Université Paris-Saclay, and obtained his Habilitation to Direct Research (HDR) from Nantes Université. He began his career in 1995 at Sanofi, where he was responsible for designing synthetic vectors for gene therapy within the GenCell department in Vitry-sur-Seine. 

From 1999 to 2000, he led a DNA vaccination program at Sanofi Pasteur in Lyon, after which he became a researcher at Centre national de la recherche scientifique (CNRS). He is currently a Research Director within the joint Institut national de la santé et de la recherche médicale/CNRS research unit hosted at Nantes Université, entitled Immunology and New Concepts in Immunotherapy. He pioneered the discovery of new synthetic vectors, named Nanotaxi™. These next-generation vectors now make it possible to overcome technological barriers in the delivery of messenger RNA and DNA molecules for therapeutic and vaccination purposes, respectively. 

Bruno Pitard has recently been awarded funding under the Impact Santé program as part of France 2030 for his project ReNAissance. Funded with €3 millions, ReNAissance aims to revolutionize antiviral treatments through messenger RNA technologies.

He is also the founder of the company In-Cell-Art, together with a Nobel Prize laureate. For 13 years, he served on the scientific board of the French association Vaincre la Mucoviscidose. He is Associate Editor of the journal Current Gene Therapy. He has authored more than 100 scientific publications and, at the invitation of the publisher Elsevier (Oxford), contributed to the 2017 revised edition of the book Comprehensive Supramolecular Chemistry.